CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database


    • TOP

    Alain S

    Mutations:

    Mutant Gene Virus Reference
    P10L UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    L11P UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    P12L UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A58T UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    D81N UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A83V UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A84P UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A84V UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    K90R UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    H97R UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    L133I UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A134T UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    E229D UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    N289D UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    D294N UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    D294G UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    H297Y UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    D298G UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    N300G UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    P307L UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    V310A UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    H313Y UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    D351N UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    S363W UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    I367V UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    G421E UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    R465C UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    T519A UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A520V UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    R531Q UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    H557Q UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A558V UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A565T UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    P571T UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    H606Y UL27 Human betaherpesvirus 5 Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A4T UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    D12E UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    G16A UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E17A UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E17del UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    Q23K UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    D24G UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    S28F UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E39D UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    D40N UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E42G UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    G56D UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    G61D UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    L70I UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    A95V UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    V113L UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    S153P UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    N408H UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N408H UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N408H UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N408S UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    N408S UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    N408S UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    G441S UL54 Human betaherpesvirus 5 Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    F460S UL54 Human betaherpesvirus 5 Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    N495K UL54 Human betaherpesvirus 5 A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( 2006)
    N495K UL54 Human betaherpesvirus 5 A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( 2006)
    N495K UL54 Human betaherpesvirus 5 A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( 2006)
    L501F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L501F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L501F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503A UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503A UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503A UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    R512C UL54 Human betaherpesvirus 5 Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    K513Q UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    K513Q UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    K513Q UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    D515Y UL54 Human betaherpesvirus 5 Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    D515Y UL54 Human betaherpesvirus 5 Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    D515Y UL54 Human betaherpesvirus 5 Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    P522T UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    P522T UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    P522T UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    C524del UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    C524del UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    C524del UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    A543V UL54 Human betaherpesvirus 5 Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    L545F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L545F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L545F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T552S UL54 Human betaherpesvirus 5 Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. (May 2022)
    T552S UL54 Human betaherpesvirus 5 Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. (May 2022)
    T552S UL54 Human betaherpesvirus 5 Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. (May 2022)
    C590F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    C590F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    C590F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    V787E UL54 Human betaherpesvirus 5 Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019)
    V787E UL54 Human betaherpesvirus 5 Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019)
    V787E UL54 Human betaherpesvirus 5 Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019)
    A928T UL54 Human betaherpesvirus 5 Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    A928T UL54 Human betaherpesvirus 5 Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    A928T UL54 Human betaherpesvirus 5 Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    981-982del UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    981-982del UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    981-982del UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    E2K UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V12L UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    D242G UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A327V UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    F345L UL56 Human betaherpesvirus 5 Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    E393K UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A425V UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    G436E UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    M442T UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A444G UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    S445N UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    N446del UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    449-451del UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    T452I UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    S454N UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    G460V UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A464T UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V471A UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V476A UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    E485G UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    R507C UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    Q577R UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    D586N UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A648R UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A648S UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    L658F UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    S749N UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V778A UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V793A UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    P800L UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    P803A UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A812E UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    L831M UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    G840A UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    S848N UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    T37A UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    L89P UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    D94N UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    K95E UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    H216R UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    G239C UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    Q244H UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    Q249H UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    K253Q UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    K253T UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    E254A UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    R258P UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    A283P UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    N294D UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    S345A UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    T448I UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    C511F UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    I531V UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    L548V UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    G635S UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    A663V UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    D665E UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    A668P UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    F671S UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    R672K UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    E596Q UL97 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)

    Tilloy et al., 2024
    Interdeposit Digital Number: IDDN.FR.001.420004.000.S.X.2024.000.31230